Clinical trials: Dual Antiplatelet Therapy
Ischemic Stroke, Acute
Ticagrelor With Aspirin Dual Antiplatelet Therapy Combined With Intravenous Thrombolysis for Ischemic Stroke
Early antiplatelet therapy is promising for further improvement of functional prognosis on the basis of intravenous thrombolytic therapy.
- Trial name
- TAPIS (NCT06316570)
- Testing
- Early Dual Antiplatelet Therapy
- Where
- 60 sites in China
- Volunteers
- 1,382 people
- Sponsor
- Beijing Tiantan Hospital
Atrial Fibrillation, Stroke
Anticoagulation in Stent Intervention
Objective: The main objective is to evaluate the pattern of dual antiplatelet therapy (aspirin, 300 mg / day + clopidogrel 75 mg / day) compared to the use of the triple regimen (Acenocoumarol as control + acetylsalicylic acid…
- Trial name
- MUSICA-2 (NCT01141153)
- Testing
- Acetylsalicylic Acid + clopidogrel + acenocoumarol, Acetylsalicylic Acid + clopidogrel
- Where
- 11 sites in Spain
- Volunteers
- 304 people
- Sponsor
- Hospital Universitari Vall d'Hebron Research Institute
Coronary Artery Disease
Tailoring P2Y12 Inhibiting Therapy in Patients Requiring Oral Anticoagulation After PCI
Clopidogrel is the P2Y12 inhibitor of choice in PCI patients requiring OAC. However, concerns have been raised based on the notion that a considerable number of patients may have inadequate response to clopidogrel.
- Trial name
- SWAP-AC-2 (NCT04483583)
- Testing
- Ticagrelor 60mg, Clopidogrel
- Where
- United States
- Volunteers
- 81 people
- Sponsor
- University of Florida
Stable Angina, Coronary Artery Disease
OCT-Guided Stent Optimization for Short-Duration Dual Antiplatelet Therapy in Stable Angina
This study aims to evaluate whether the use of optical coherence tomography (OCT), an advanced intravascular imaging tool, can improve stent implantation results and make it possible to shorten the duration of dual antiplatelet…
- Trial name
- COMFORT-SHORT (NCT07198529)
- Testing
- Short DAPT, Standard DAPT, Extended DAPT
- Where
- South Korea
- Volunteers
- 130 people
- Sponsor
- Korea University Guro Hospital
Coronary Artery Disease (CAD)
1-Month Versus 6-Month Dual Antiplatelet Therapy After Successful Drug-Coated Balloon-Only Percutaneous Coronary Intervention
This study will compare the clinical outcomes of a 1-month dual antiplatelet therapy (DAPT) strategy with a standard 6-month DAPT strategy in patients undergoing successful drug-coated balloon-only percutaneous coronary…
- Trial name
- ADAPT-DCB (NCT07879430)
- Testing
- 1-Month DAPT, 6-Month DAPT
- Volunteers
- 1,258 people
- Sponsor
- Ulsan University Hospital
Platelet Inhibition, Coronary Stent Implantation
Individualizing Dual Antiplatelet Therapy After Percutaneous Coronary Intervention - The IDEAL-PCI Registry
The purpose of this study is to determine the efficacy and safety of a routine individualized antiplatelet therapy after coronary stent implantation by evaluating "on-treatment" platelet reactivity with Multiple Electrode…
- Trial name
- IDEAL-PCI (NCT01515345)
- Testing
- prasugrel or ticagrelor, Clopidogrel
- Where
- Austria
- Volunteers
- 1,008 people
- Sponsor
- Kaiser Franz Josef Hospital
Gastrointestinal Injury, Ischemic Heart Disease
Mono- Versus Dual antiPlatelet Therapy During 6-12 Months After New Generation Drug Eluting Stent Implantation
Long-term DAPT is recommended after percutaneous coronary intervention (PCI) in patients with coronary artery disease. However, antiplatelet therapy may have adverse consequences, the most common of which is gastrointestinal…
- Trial name
- OPT-PEACE (NCT03198741)
- Testing
- Aspirin + clopidogrel, Clopidogrel monotherapy, Aspirin monotherapy
- Where
- China
- Volunteers
- 783 people
- Sponsor
- Shenyang Northern Hospital
Coronary Artery Disease
A Randomized Controlled Trial With Resolute Onyx in One Month Dual Antiplatelet Therapy (DAPT) for High-Bleeding Risk Patients
The purpose of this study is to evaluate the clinical safety and effectiveness of the Resolute Onyx stent in subjects deemed at high risk for bleeding and/or medically unsuitable for more than 1 month DAPT treatment receiving…
- Trial name
- Onyx ONE (NCT03344653)
- Testing
- Medtronic Resolute Onyx Zotarolimus-Eluting Coronary Stent System, Biosensors BioFreedom BA9 Drug Coated Coronary Stent
- Where
- 89 sites in Australia, Austria and 21 more
- Volunteers
- 2,000 people
- Sponsor
- Medtronic Vascular
Acute Coronary Syndrome
DCS Versus DES for One-month DAPT in Patients With ACS: ONE-PASS Trial
To test whether the polymer-free drug-coated stent (DCS) BioFreedom is noninferior to the biodegradable polymer drug-eluting stent (DES) Ultimaster in terms of 1-year patient-oriented composite endpoint (POCE, composite of…
- Trial name
- ONE-PASS (NCT05305482)
- Testing
- Drug-coated stent, Drug-eluting stent
- Where
- South Korea
- Volunteers
- 3,520 people
- Sponsor
- Yonsei University
Stroke, Ischemic Attack, Transient
Platelet Reactivity in Acute Non-disabling Cerebrovascular Events
Ticagrelor is a reversible and direct-acting oral antagonist of the P2Y12 (Purinergic receptor P2Y, G-protein coupled, 12) receptor for adenosine diphosphate, which provides faster, greater, and more consistent P2Y12 inhibition…
- Trial name
- PRINCE (NCT02506140)
- Testing
- Ticagrelor and Acetylsalicylic acid, Clopidogrel and Acetylsalicylic acid
- Where
- 25 sites in China
- Volunteers
- 675 people
- Sponsor
- Beijing Tiantan Hospital
Ischemic Stroke, TIA
Apixaban Versus Dual-antiplatelet Therapy (Clopidogrel and Aspirin) in Acute Non-disabling Cerebrovascular Events
Nondisabling cerebrovascular events represent the largest group of cerebrovascular disease with a high risk of recurrent stroke.
- Trial name
- ADANCE (NCT01924325)
- Testing
- Apixaban, Clopidogrel, Aspirin
- Where
- China
- Volunteers
- 10,000 people
- Sponsor
- Xijing Hospital
Coronary Artery Disease
Short-term Dual Antiplatelet Therapy After Deployment of Bioabsorbable Polymer Everolimus-eluting Stent
To compare the clinical outcomes of P2Y12 antagonist monotherapy with aspirin plus P2Y12 antagonist following 3-month of DAPT in patients undergoing PCI with bioabsorbable polymer Everolimus-eluting stents (Synergy®)
- Trial name
- NCT03447379
- Testing
- P2Y12 antagonist monotherapy, Aspirin plus P2Y12 antagonist
- Where
- South Korea
- Volunteers
- 1,452 people
- Sponsor
- Gangnam Severance Hospital
Coronary Artery Disease
Tailoring Bleeding Reduction Approaches in Patients Undergoing PCI
Two strategies have both proven to be effective in reducing bleeding complications while preserving efficacy compared with maintaining long-term DAPT with aspirin and a potent P2Y12 inhibitor: a) DAPT de-escalation (i.e.…
- Trial name
- TAILOR BLEED (NCT05681702)
- Testing
- aspirin plus clopidogrel, prasugrel or ticagrelor
- Where
- United States
- Volunteers
- 84 people, healthy volunteers welcome
- Sponsor
- University of Florida
Coronary Artery Disease
Synergy Between Stent and Drugs to Avoid Ischemic Recurrences After Percutaneous Coronary Intervention
The duration of dual antiplatelet treatment (i.e. asprin and clopidogrel) after drug-eluting stent implantation is highly debated.
- Trial name
- PRODIGY (NCT00611286)
- Testing
- clopidogrel treatment after bare metal stent implantation, clopidogrel after zotarolimus-eluting stent implantation, clopidogrel after paclitaxel-eluting stent implantation
- Where
- Italy
- Volunteers
- 1,700 people
- Sponsor
- Marco Valgimigli
CORONARY ARTERY DISEASE
"Potential Effect of Acute and Chronic Caffeine Administration on Platelet Reactivity in Patient With Coronary Artery Disease on Dual Antiplatelet Therapy"
Prasugrel is a potent thienopyridine antiplatelet agent that selectively and irreversibly inhibits ADP-induced platelet aggregation mediated by the P2Y12 receptor.
- Trial name
- CyCLOPS (NCT02054988)
- Testing
- caffeine, not caffeine
- Where
- Italy
- Volunteers
- 240 people, healthy volunteers welcome
- Sponsor
- University of Roma La Sapienza
High Bleeding Risk Patients, Cardiology
Dual Anti-Platelet Optimized Stent for High Bleeding Risk Patient
High risk of bleeding (HBR) is a determining factor for the duration of dual antiplatelet therapy (DAPT). Recent studies have shown that the use of one-month DAPT is beneficial in terms of ischemic as well as hemorrhagic events…
- Conditions
- High Bleeding Risk Patients, Cardiology, Stent Implantation, DAPT(Dual Antiplatelet Therapy)
- Trial name
- DIOHR (NCT07140133)
- Where
- France
- Volunteers
- 1,200 people
- Sponsor
- University Hospital, Grenoble
Stroke, Thrombolysis
Efficacy and Safety of Intravenous Thrombolysis in Branch Atheromatous Disease
Rationale and Relevance: Branch Atheromatous Disease (BAD) describes an atherosclerotic occlusion of one of the deep penetrating cerebral arteries, including the lenticulostriate artery (LSA), paramedian pontine artery (PPA), and…
- Conditions
- Stroke, Thrombolysis, DAPT(Dual Antiplatelet Therapy), SAPT(Single Antiplatelet Therapy)
- Trial name
- NCT07299994
- Where
- 8 sites in Austria, Germany and 1 more
- Volunteers
- 462 people
- Sponsor
- Sigmund Freud PrivatUniversitat
Percutaneous Transluminal Coronary Angioplasty, Coronary Disease
Optimal Duration of Antiplatelet Therapy After Bioresorbable Vascular Scaffold Implantation to Reduce Late Coronary Arterial Thrombotic Events
The purpose of this study is to evaluate optimal duration of antiplatelet therapy after Bioresorbable Vascular Scaffold implantation to reduce late coronary arterial thrombotic events.
- Trial name
- BVS LATE (NCT02939872)
- Testing
- aspirin and clopidogrel, Clopidogrel only
- Where
- 2 sites in South Korea
- Volunteers
- 238 people
- Sponsor
- Seung-Jung Park
Coronary Artery Disease
Effect of Different Anti-platelet Strategies on the Long-term Outcome After Sirolimus Drug-eluting Stent Implantation
The study aims to assess the effectiveness of dual antiplatelet therapy, aspirin alone versus steeply discontinued clopidogrel plus aspirin in preventing clinical MACE events.Our subject is beyond a 12-month period patients…
- Trial name
- EASTS (NCT01233167)
- Testing
- clopidogrel
- Volunteers
- 5,232 people
- Sponsor
- Sir Run Run Shaw Hospital
Coronary Artery Disease
Pharmacodynamic Effects of Dabigatran in Patients on Dual Antiplatelet Therapy
Dual antiplatelet therapy consisting of aspirin and clopidogrel is the cornerstone of treatment for prevention of atherothrombotic events in patients with coronary artery disease (CAD) undergoing percutaneous coronary…
- Trial name
- NCT01852162
- Testing
- Dabigatran
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- University of Florida